EP2899210A3 - Dual specificity antibodies and methods of making and using - Google Patents
Dual specificity antibodies and methods of making and using Download PDFInfo
- Publication number
- EP2899210A3 EP2899210A3 EP15154039.0A EP15154039A EP2899210A3 EP 2899210 A3 EP2899210 A3 EP 2899210A3 EP 15154039 A EP15154039 A EP 15154039A EP 2899210 A3 EP2899210 A3 EP 2899210A3
- Authority
- EP
- European Patent Office
- Prior art keywords
- antibodies
- methods
- alpha
- dual specificity
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000009977 dual effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 102000003777 Interleukin-1 beta Human genes 0.000 abstract 4
- 108090000193 Interleukin-1 beta Proteins 0.000 abstract 4
- 102000004125 Interleukin-1alpha Human genes 0.000 abstract 4
- 108010082786 Interleukin-1alpha Proteins 0.000 abstract 4
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 230000001627 detrimental effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21537900P | 2000-06-29 | 2000-06-29 | |
EP10182393A EP2386575A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP09150437A EP2042518A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP01950668A EP1297142B1 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
Related Parent Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP10182393A Division EP2386575A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP09150437A Division EP2042518A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP01950668A Division EP1297142B1 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2899210A2 EP2899210A2 (en) | 2015-07-29 |
EP2899210A3 true EP2899210A3 (en) | 2015-11-18 |
Family
ID=22802758
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15154039.0A Withdrawn EP2899210A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP09150437A Withdrawn EP2042518A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP10182393A Withdrawn EP2386575A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP01950668A Expired - Lifetime EP1297142B1 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09150437A Withdrawn EP2042518A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP10182393A Withdrawn EP2386575A3 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
EP01950668A Expired - Lifetime EP1297142B1 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
Country Status (27)
Country | Link |
---|---|
US (5) | US7491516B2 (en) |
EP (4) | EP2899210A3 (en) |
JP (2) | JP4955185B2 (en) |
KR (2) | KR100919593B1 (en) |
CN (3) | CN101525384A (en) |
AT (1) | ATE420958T1 (en) |
AU (1) | AU2001271636A1 (en) |
BG (1) | BG66209B1 (en) |
BR (1) | BR0112026A (en) |
CA (1) | CA2411374C (en) |
CZ (1) | CZ2003291A3 (en) |
DE (1) | DE60137421D1 (en) |
EC (1) | ECSP024409A (en) |
ES (1) | ES2319866T3 (en) |
HK (1) | HK1055316A1 (en) |
HU (1) | HUP0301002A3 (en) |
IL (3) | IL153567A0 (en) |
MX (1) | MXPA02012867A (en) |
NO (1) | NO20026239L (en) |
NZ (1) | NZ523080A (en) |
PE (1) | PE20020132A1 (en) |
PL (1) | PL208069B1 (en) |
SK (1) | SK1152003A3 (en) |
TW (2) | TW200516083A (en) |
UY (1) | UY26807A1 (en) |
WO (1) | WO2002002773A2 (en) |
ZA (1) | ZA200210109B (en) |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6617129B2 (en) * | 1997-06-27 | 2003-09-09 | Human Genome Sciences, Inc. | Human NK-3 related prostate specific gene-1 |
SK1152003A3 (en) | 2000-06-29 | 2003-07-01 | Abbott Lab | Dual specificity antibodies and methods of making and using |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
WO2003002609A2 (en) * | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
GB0115841D0 (en) | 2001-06-28 | 2001-08-22 | Medical Res Council | Ligand |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
PT2314629E (en) | 2002-07-18 | 2014-01-22 | Merus B V | Recombinant production of mixtures of antibodies |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
US20050271660A1 (en) * | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20110223168A1 (en) * | 2002-12-27 | 2011-09-15 | Greg Winter | Ligand that has binding specificity for il-4 and/or il-13 |
GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
ES2408582T3 (en) | 2003-05-30 | 2013-06-21 | Merus B.V. | Fab library for the preparation of a mixture of antibodies |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
EP1761561B1 (en) * | 2004-01-20 | 2015-08-26 | KaloBios Pharmaceuticals, Inc. | Antibody specificity transfer using minimal essential binding determinants |
TWI439284B (en) * | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | Multiple-variable dose regimen for treating tnfα-related disorders |
CN101426526B (en) * | 2004-04-26 | 2012-06-20 | 森托科尔公司 | Solution phase biopanning method using engineered decoy proteins |
US7514539B2 (en) | 2004-04-26 | 2009-04-07 | Centocor, Inc. | Epitope directed selection of antibodies to murine tissue factor |
US7790405B2 (en) | 2004-04-26 | 2010-09-07 | Centocor, Inc. | Solution phase biopanning method using engineered decoy proteins |
WO2005118642A2 (en) | 2004-06-01 | 2005-12-15 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
US7566772B2 (en) | 2005-01-26 | 2009-07-28 | Amgen Fremont Inc. | Antibodies against interleukin-1β |
KR100675791B1 (en) * | 2005-02-04 | 2007-02-02 | 제주대학교 산학협력단 | Automatic feeding system for the fish breeding in landscape |
CA2608058C (en) | 2005-05-12 | 2013-09-10 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
US20090130652A1 (en) * | 2005-06-23 | 2009-05-21 | Crucell Holland B.V. | Optimization of West Nile Virus Antibodies |
SI2298815T1 (en) | 2005-07-25 | 2015-08-31 | Emergent Product Development Seattle, Llc | B-cell reduction using CD37-specific and CD20-specific binding molecules |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500355A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
SG2014010029A (en) | 2005-08-19 | 2014-08-28 | Abbott Lab | Dual variable domain immunoglobin and uses thereof |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
WO2007042524A2 (en) * | 2005-10-14 | 2007-04-19 | Novo Nordisk A/S | Treating diabetes using inhibitors of il-1 |
RU2008144802A (en) * | 2006-04-14 | 2010-05-20 | Новартис АГ (CH) | APPLICATION OF ANTIBODIES AGAINST IL-1 FOR TREATMENT OF EYE DISORDERS |
EP2395018B1 (en) | 2006-06-06 | 2016-01-27 | Crucell Holland B.V. | Human binding molecules having killing activity against staphylococci and uses thereof |
CA3149553C (en) | 2006-06-12 | 2023-11-21 | Aptevo Research And Development Llc | Single-chain multivalent binding proteins with effector function |
JP2009545747A (en) * | 2006-08-02 | 2009-12-24 | カリフォルニア インスティチュート オブ テクノロジー | Method and system for detecting and / or sorting targets |
EP2471816A1 (en) * | 2006-08-30 | 2012-07-04 | Genentech, Inc. | Multispecific antibodies |
WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
US8324350B2 (en) * | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
WO2008150491A2 (en) | 2007-05-31 | 2008-12-11 | Abbott Laboratories | BIOMARKERS PREDICTIVE OF THE RESPONSIVENESS TO TNFα INHIBITORS IN AUTOIMMUNE DISORDERS |
ES2622460T3 (en) | 2007-09-26 | 2017-07-06 | Ucb Biopharma Sprl | Fusions of antibodies with double specificity |
AU2008338421A1 (en) | 2007-12-17 | 2009-06-25 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
CA2717576A1 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 binding proteins |
US8013125B2 (en) * | 2008-03-03 | 2011-09-06 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
MX340204B (en) | 2008-04-11 | 2016-06-30 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof. |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
RU2010153580A (en) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND THEIR APPLICATION |
CA2725666A1 (en) * | 2008-06-03 | 2009-12-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
JP5674654B2 (en) | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | Prostaglandin E2 double variable domain immunoglobulin and use thereof |
WO2010027981A1 (en) | 2008-09-03 | 2010-03-11 | Genentech, Inc. | Multispecific antibodies |
EP2341936A4 (en) * | 2008-09-05 | 2012-07-25 | Xoma Technology Ltd | METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES |
CA2737056C (en) * | 2008-09-12 | 2018-10-30 | Xbiotech Inc. | Targeting pathogenic monocytes |
CA2737241C (en) | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
UA102722C2 (en) * | 2009-01-29 | 2013-08-12 | Эббви Инк. | Il-1 binding proteins |
US8835610B2 (en) | 2009-03-05 | 2014-09-16 | Abbvie Inc. | IL-17 binding proteins |
WO2010112193A1 (en) * | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
CN101957365B (en) * | 2009-07-21 | 2013-08-07 | 卫生部北京医院 | Kit for detecting cyclic citrullinated peptide (CCP) and immunoglobulin G (IgG) resistant bispecific antibody |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
PE20121647A1 (en) | 2009-08-29 | 2012-12-31 | Abbvie Inc | THERAPEUTIC BINDING PROTEINS TO DLL4 |
TW201119673A (en) * | 2009-09-01 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
WO2011047266A1 (en) * | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Il-1 binding proteins |
TW201119676A (en) * | 2009-10-15 | 2011-06-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
UY32979A (en) | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CA2780069C (en) | 2009-12-08 | 2018-07-17 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
CA2786745A1 (en) * | 2010-01-12 | 2011-07-21 | Oncomed Pharmaceuticals, Inc. | Wnt-binding agents and uses thereof |
SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
KR20180053775A (en) * | 2010-04-23 | 2018-05-23 | 제넨테크, 인크. | Production of heteromultimeric proteins |
HUE033063T2 (en) | 2010-05-14 | 2017-11-28 | Abbvie Inc | Il-1 binding proteins |
US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN103154032A (en) * | 2010-08-13 | 2013-06-12 | 弗·哈夫曼-拉罗切有限公司 | Antibodies to IL-1beta and IL-18, for treatment of disease |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
RU2627171C2 (en) | 2010-12-21 | 2017-08-03 | Эббви Инк. | Il-1 alpha and beta bispecific immunoglobulins with double variable domains and their application |
WO2012109373A2 (en) * | 2011-02-08 | 2012-08-16 | Abbott Laboratories | Treatment of osteoarthritis and pain |
WO2012163521A1 (en) | 2011-05-27 | 2012-12-06 | Dutalys | Removal of monomeric targets |
SI2726510T1 (en) | 2011-05-27 | 2023-06-30 | F. Hoffmann - La Roche Ag | Dual targeting |
WO2012176779A1 (en) | 2011-06-20 | 2012-12-27 | 協和発酵キリン株式会社 | Anti-erbb3 antibody |
WO2013059439A2 (en) | 2011-10-21 | 2013-04-25 | Dyax Corp. | Combination therapy comprising an mmp-14 binding protein |
CA2853114A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Bispecific immunobinders directed against tnf and il-17 |
AR088513A1 (en) | 2011-10-24 | 2014-06-18 | Abbvie Inc | IMMUNO LINKERS AGAINST SCLEROSTINE |
WO2013078135A2 (en) * | 2011-11-21 | 2013-05-30 | Abbott Laboratories | Il-1 binding proteins |
RU2482181C1 (en) * | 2011-12-07 | 2013-05-20 | Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН | D11 human multiple myeloma cell line used for monoclonal antibody technology |
CA2855570A1 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
US10118958B2 (en) | 2011-12-14 | 2018-11-06 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
KR101963230B1 (en) | 2011-12-26 | 2019-03-29 | 삼성전자주식회사 | Protein complex comprising multi-specific monoclonal antibodies |
AR090047A1 (en) | 2011-12-30 | 2014-10-15 | Abbvie Inc | DUAL VARIABLE DOMAIN OF IMMUNOGLOBULINS AND THEIR USES |
BR112014015851A2 (en) | 2011-12-30 | 2019-09-24 | Abbvie Inc | double specific binding proteins directed against il-13 and / or il-17 |
ES2676725T3 (en) | 2012-01-27 | 2018-07-24 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of diseases associated with the degeneration of neurites |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
HUE045944T2 (en) | 2012-04-20 | 2020-02-28 | Merus Nv | Methods and means for the production of heterodimeric ig-like molecules |
US9670276B2 (en) | 2012-07-12 | 2017-06-06 | Abbvie Inc. | IL-1 binding proteins |
KR101911438B1 (en) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | Bispecific antigen binding protein complex and preparation methods of bispecific antibodies |
SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
TW201422236A (en) * | 2012-11-01 | 2014-06-16 | Abbvie Inc | Stable dual variable domain immunoglobulin protein formulations |
JP2016501881A (en) | 2012-12-04 | 2016-01-21 | アッヴィ・インコーポレイテッド | Bispecific binding protein that permeates the blood-brain barrier (BBB) |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
MX2015008446A (en) | 2012-12-28 | 2016-10-26 | Abbvie Inc | Multivalent binding protein compositions. |
US20140219913A1 (en) * | 2012-12-28 | 2014-08-07 | Abbvie, Inc. | Dual Specific Binding Proteins Having a Receptor Sequence |
US20140242077A1 (en) | 2013-01-23 | 2014-08-28 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
EP2970457A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against tnf |
CN105324396A (en) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | Dual specific binding proteins directed against il-1 beta and il-17 |
JP6581572B2 (en) | 2013-06-07 | 2019-09-25 | デューク ユニバーシティ | Complement factor H inhibitor |
CN103308697B (en) * | 2013-06-09 | 2014-11-26 | 卫生部北京医院 | Kit used for detecting natural bispecific antibody resistant to HCV (hepatitis C virus) coded non-structural proteins NS3 and NS5 |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
KR20160055275A (en) | 2013-09-17 | 2016-05-17 | 유니버시티 헬스 네트워크 | Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in the methods of treatment |
EA201600303A1 (en) | 2013-09-30 | 2016-11-30 | Чугаи Сеияку Кабушики Каиша | METHOD OF OBTAINING AN ANTIGEN-BINDING MOLECULE USING A MODIFIED HELPER PHAG |
CN105849124B (en) | 2013-12-20 | 2022-04-12 | 豪夫迈·罗氏有限公司 | Dual specificity antibodies |
US20160000936A1 (en) | 2014-06-10 | 2016-01-07 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
US20160002343A1 (en) | 2014-06-11 | 2016-01-07 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
JP6655302B2 (en) * | 2015-05-29 | 2020-02-26 | デンカ生研株式会社 | Method for detecting subject, immunoassay instrument and monoclonal antibody therefor |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
US20170073420A1 (en) | 2015-09-11 | 2017-03-16 | Abbvie Inc. | Methods for treating relapsing forms of multiple sclerosis |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
JP6734919B2 (en) * | 2015-10-02 | 2020-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cell-based FRET assay for measuring simultaneous binding |
LT3356411T (en) | 2015-10-02 | 2021-09-10 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
US11219645B2 (en) | 2015-11-18 | 2022-01-11 | Duke University | Tumor infiltrating lymphocytes for treatment of cancer |
WO2017156500A1 (en) | 2016-03-11 | 2017-09-14 | Scholar Rock, Inc. | Tgfb1-binding immunoglobulins and use thereof |
TW201803900A (en) | 2016-06-01 | 2018-02-01 | 艾伯維有限公司 | Methods for treating spinal cord injury and pain |
MX2019003473A (en) | 2016-10-03 | 2019-10-15 | Abbott Lab | Improved methods of assessing uch-l1 status in patient samples. |
JP7157744B2 (en) | 2017-01-06 | 2022-10-20 | スカラー ロック インコーポレイテッド | Isoform-specific, context-tolerant TGFβ1 inhibitors and uses thereof |
CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
CN110392692B (en) | 2017-04-03 | 2023-07-21 | 豪夫迈·罗氏有限公司 | Immunoconjugates of anti-PD-1 antibodies with mutant IL-2 or with IL-15 |
KR102408873B1 (en) | 2017-04-05 | 2022-06-15 | 에프. 호프만-라 로슈 아게 | Bispecific antibodies specifically binding to pd1 and lag3 |
JP7344797B2 (en) | 2017-04-15 | 2023-09-14 | アボット・ラボラトリーズ | Methods to aid in hyperacute diagnosis and determination of traumatic brain injury in human subjects using early biomarkers |
CN110603449A (en) | 2017-04-28 | 2019-12-20 | 雅培实验室 | Method for determining traumatic brain injury using early biomarkers from at least two samples of the same human subject for aiding hyperacute diagnosis |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
CN110651190A (en) | 2017-05-25 | 2020-01-03 | 雅培实验室 | Method for using early biomarkers to help determine whether to perform imaging on a human subject who has suffered or may have suffered a head injury |
AU2018275235A1 (en) | 2017-05-30 | 2019-10-31 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
EP3649474A1 (en) | 2017-07-03 | 2020-05-13 | Abbott Laboratories | Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
JP7311425B2 (en) | 2017-11-08 | 2023-07-19 | 協和キリン株式会社 | Bispecific antibodies that bind to CD40 and EpCAM |
WO2019113525A2 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1) |
WO2019112860A1 (en) | 2017-12-09 | 2019-06-13 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1 |
BR112020010430A2 (en) | 2017-12-29 | 2020-11-24 | Abbott Laboratories | biomarkers and innovative methods to diagnose and evaluate traumatic brain injury |
JP2021531254A (en) | 2018-07-11 | 2021-11-18 | スカラー ロック インコーポレイテッドScholar Rock, Inc. | High affinity isoform-selective TGFβ1 inhibitor, and its use |
EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
PT3677278T (en) | 2018-07-11 | 2022-02-03 | Scholar Rock Inc | Isoform selective tgfbeta1 inhibitors and use thereof |
TW202039581A (en) | 2018-12-28 | 2020-11-01 | 日商協和麒麟股份有限公司 | Bispecific antibody binding to TfR |
EP3931573A1 (en) | 2019-03-01 | 2022-01-05 | Abbott Laboratories | Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease |
EP3971293A4 (en) | 2019-05-15 | 2023-02-08 | Kyowa Kirin Co., Ltd. | Bispecific antibody capable of binding to cd40 and gpc3 |
KR20220008820A (en) | 2019-05-15 | 2022-01-21 | 쿄와 기린 가부시키가이샤 | Bispecific antibody that binds to CD40 and FAP |
BR112022013733A2 (en) | 2020-01-11 | 2022-11-01 | Scholar Rock Inc | TGFBETA INHIBITORS AND THEIR USE |
WO2021142448A2 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock,Inc. | Tgf-beta inhibitors and use thereof |
CA3175523A1 (en) | 2020-04-13 | 2021-10-21 | Antti Virtanen | Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample |
CN111793131A (en) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | Antibody pair for detecting content of PF4 in serum and application thereof |
EP4193149A1 (en) | 2020-08-04 | 2023-06-14 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
US20220170948A1 (en) | 2020-12-01 | 2022-06-02 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
CA3216320A1 (en) | 2021-05-18 | 2022-11-24 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
WO2022266034A1 (en) | 2021-06-14 | 2022-12-22 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
WO2023288277A1 (en) | 2021-07-14 | 2023-01-19 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgfb1 and uses thereof |
WO2023019019A2 (en) * | 2021-08-13 | 2023-02-16 | Abwiz Bio, Inc. | Humanization, affinity maturation, and optimization methods for proteins and antibodies |
CA3230038A1 (en) | 2021-08-31 | 2023-03-09 | Hongwei Zhang | Methods and systems of diagnosing brain injury |
AU2022354059A1 (en) | 2021-09-30 | 2024-03-28 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
US5756095A (en) * | 1992-05-22 | 1998-05-26 | The Research And Development Institute, Inc. | Antibodies with specificity for a common epitope on E-selectin and L-selectin |
US5969108A (en) * | 1990-07-10 | 1999-10-19 | Medical Research Council | Methods for producing members of specific binding pairs |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US126603A (en) | 1872-05-07 | Improvement in machines for sawing staves | ||
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
FR2577377B1 (en) * | 1985-02-21 | 1989-06-16 | Albaret Sa | METHOD FOR AVOIDING THE SKATING OF A TRACTOR EQUIPPED WITH A HYDRAULIC LIFTING WITH A TOOL BURIED IN THE GROUND, AND TRACTOR EQUIPMENT FOR IMPLEMENTING THIS METHOD |
US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
AU4308689A (en) | 1988-09-02 | 1990-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2919890B2 (en) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor |
ATE139258T1 (en) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | GENERATION OF XENOGENE ANTIBODIES |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
KR100272077B1 (en) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
PT1696031E (en) | 1991-12-02 | 2010-06-25 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1996000081A1 (en) * | 1994-06-24 | 1996-01-04 | Immunex Corporation | Controlled release polypeptide compositions and methods of treating inflammatory bowel disease |
EP0822830B1 (en) | 1995-04-27 | 2008-04-02 | Amgen Fremont Inc. | Human anti-IL-8 antibodies, derived from immunized xenomice |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
DK1143006T3 (en) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vectors / DNA sequences from human combinatorial antibody libraries |
TR199801532T2 (en) | 1996-02-09 | 1998-11-23 | Basf Aktiengesellschaft | Human antibodies that bind human TNFalpha. |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
IL119587A (en) * | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
CA2273194C (en) | 1996-12-03 | 2011-02-01 | Abgenix, Inc. | Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom |
CN1238366C (en) | 1997-01-21 | 2006-01-25 | 综合医院公司 | Selection of proteins using RNA-protein fusions |
EP0985033A4 (en) | 1997-04-04 | 2005-07-13 | Biosite Inc | Polyvalent and polyclonal libraries |
WO1998049286A2 (en) | 1997-05-01 | 1998-11-05 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US6680380B1 (en) | 1998-09-18 | 2004-01-20 | Schering Corporation | Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods |
CA2669512A1 (en) | 1999-03-25 | 2000-09-28 | Abbott Gmbh & Co. Kg | Human antibodies that bind human il-12 and methods for producing |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
SK1152003A3 (en) | 2000-06-29 | 2003-07-01 | Abbott Lab | Dual specificity antibodies and methods of making and using |
WO2003002609A2 (en) | 2001-06-28 | 2003-01-09 | Domantis Limited | Dual-specific ligand and its use |
CN1678634A (en) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | Immunoglobulin single variable antigen combination area and its opposite constituent |
AU2006321364B2 (en) | 2005-12-01 | 2011-11-10 | Domantis Limited | Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
US8324350B2 (en) | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
-
2001
- 2001-06-28 SK SK115-2003A patent/SK1152003A3/en not_active Application Discontinuation
- 2001-06-28 NZ NZ523080A patent/NZ523080A/en not_active IP Right Cessation
- 2001-06-28 PL PL359995A patent/PL208069B1/en not_active IP Right Cessation
- 2001-06-28 ES ES01950668T patent/ES2319866T3/en not_active Expired - Lifetime
- 2001-06-28 CN CNA2009101351381A patent/CN101525384A/en active Pending
- 2001-06-28 AT AT01950668T patent/ATE420958T1/en not_active IP Right Cessation
- 2001-06-28 US US09/894,550 patent/US7491516B2/en not_active Expired - Fee Related
- 2001-06-28 DE DE60137421T patent/DE60137421D1/en not_active Expired - Lifetime
- 2001-06-28 PE PE2001000641A patent/PE20020132A1/en not_active Application Discontinuation
- 2001-06-28 EP EP15154039.0A patent/EP2899210A3/en not_active Withdrawn
- 2001-06-28 UY UY26807A patent/UY26807A1/en not_active Application Discontinuation
- 2001-06-28 EP EP09150437A patent/EP2042518A3/en not_active Withdrawn
- 2001-06-28 JP JP2002508013A patent/JP4955185B2/en not_active Expired - Fee Related
- 2001-06-28 KR KR1020027017916A patent/KR100919593B1/en not_active IP Right Cessation
- 2001-06-28 KR KR1020087018593A patent/KR20080074231A/en not_active Application Discontinuation
- 2001-06-28 IL IL15356701A patent/IL153567A0/en unknown
- 2001-06-28 MX MXPA02012867A patent/MXPA02012867A/en active IP Right Grant
- 2001-06-28 EP EP10182393A patent/EP2386575A3/en not_active Withdrawn
- 2001-06-28 HU HU0301002A patent/HUP0301002A3/en unknown
- 2001-06-28 BR BR0112026-3A patent/BR0112026A/en not_active IP Right Cessation
- 2001-06-28 CA CA2411374A patent/CA2411374C/en not_active Expired - Fee Related
- 2001-06-28 EP EP01950668A patent/EP1297142B1/en not_active Expired - Lifetime
- 2001-06-28 WO PCT/US2001/020755 patent/WO2002002773A2/en active Application Filing
- 2001-06-28 AU AU2001271636A patent/AU2001271636A1/en not_active Abandoned
- 2001-06-28 CZ CZ2003291A patent/CZ2003291A3/en unknown
- 2001-06-28 CN CN01814818A patent/CN1451043A/en active Pending
- 2001-06-28 CN CN2010105838125A patent/CN102120773B/en not_active Expired - Fee Related
- 2001-06-29 TW TW094102248A patent/TW200516083A/en unknown
- 2001-06-29 TW TW090115948A patent/TWI307716B/en not_active IP Right Cessation
-
2002
- 2002-12-12 ZA ZA200210109A patent/ZA200210109B/en unknown
- 2002-12-20 IL IL153567A patent/IL153567A/en not_active IP Right Cessation
- 2002-12-27 EC EC2002004409A patent/ECSP024409A/en unknown
- 2002-12-27 NO NO20026239A patent/NO20026239L/en not_active Application Discontinuation
-
2003
- 2003-01-21 BG BG107483A patent/BG66209B1/en unknown
- 2003-08-27 HK HK03106152.8A patent/HK1055316A1/en unknown
-
2008
- 2008-12-11 US US12/316,340 patent/US8475766B2/en not_active Expired - Lifetime
-
2010
- 2010-02-14 IL IL203955A patent/IL203955A/en not_active IP Right Cessation
-
2011
- 2011-08-31 JP JP2011188635A patent/JP2012031178A/en active Pending
-
2013
- 2013-05-23 US US13/900,841 patent/US20140155579A1/en not_active Abandoned
-
2014
- 2014-08-26 US US14/469,122 patent/US20140378666A1/en not_active Abandoned
-
2015
- 2015-03-05 US US14/639,985 patent/US20150175694A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5969108A (en) * | 1990-07-10 | 1999-10-19 | Medical Research Council | Methods for producing members of specific binding pairs |
US5756095A (en) * | 1992-05-22 | 1998-05-26 | The Research And Development Institute, Inc. | Antibodies with specificity for a common epitope on E-selectin and L-selectin |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
Non-Patent Citations (3)
Title |
---|
IBA Y ET AL: "CHANGES IN THE SPECIFICITY OF ANTIBODIES AGAINST STEROID ANTIGENS BY INTRODUCTION OF MUTATIONS INTO COMPLEMENTARITY-DETERMINING REGIONS OF THE VH DOMAIN", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 11, no. 5, 1 January 1998 (1998-01-01), pages 361 - 370, XP002953909, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/11.5.361 * |
LUGER T A ET AL: "MONOCLONAL ANTI-INTERLEUKIN 1 IS DIRECTED AGAINST A COMMON SITE OF HUMAN INTERLEUKIN 1-ALPHA AND INTERLEUKIN 1-BETA", IMMUNOBIOLOGY, vol. 172, no. 3-5, 1986, pages 346 - 356, XP008004584, ISSN: 0171-2985 * |
T. J. KUNICKI ET AL: "Molecular Determinants of Arg-Gly-Asp Ligand Specificity for beta3 Integrins", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 7, 14 February 1997 (1997-02-14), US, pages 4103 - 4107, XP055219406, ISSN: 0021-9258, DOI: 10.1074/jbc.272.7.4103 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2899210A3 (en) | Dual specificity antibodies and methods of making and using | |
EP2360184A3 (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
EP2460830A3 (en) | IL-18 binding proteins | |
CA2365281A1 (en) | Human antibodies that bind human il-12 and methods for producing | |
HUP0200537A2 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
EP1433792A8 (en) | Human receptor proteins, related reagents and methods | |
WO1999046379A3 (en) | Human receptor proteins; related reagents and methods | |
WO2003011907A3 (en) | Receptor, the use thereof, and mouse antibodies | |
BR9702101A (en) | Hybridoma and monoclonal antibody | |
AU7128098A (en) | Methods of obtaining antigens specific for fungi, antibodies for such antigens, and diagnosis of disease using such antigens and/or antibodies | |
AU4775899A (en) | Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production | |
WO2003014389A3 (en) | Method for determining susceptibility to prion disease | |
IT1293510B1 (en) | MONOCLONAL CATALYTIC ANTIBODIES FOR THE IN VIVO TRANSFORMATION OF CORTICOSTEROID PROFARMACES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20150205 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 1297142 Country of ref document: EP Kind code of ref document: P Ref document number: 2386575 Country of ref document: EP Kind code of ref document: P Ref document number: 2042518 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 16/46 20060101ALI20151013BHEP Ipc: C07K 14/545 20060101ALN20151013BHEP Ipc: A01K 67/027 20060101ALN20151013BHEP Ipc: C07K 16/24 20060101AFI20151013BHEP |
|
17P | Request for examination filed |
Effective date: 20160518 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160519 |